Antiphospholipid Antibodies, Beta 2-Glycoprotein I And Control Of Coagulation.
Funder
National Health and Medical Research Council
Funding Amount
$471,000.00
Summary
Antiphospholipid antibodies are associated with an autoimmune condition characterised by the presence of clots and recurrent miscarriages. Although the name implies that the antibodies bind phospholipid the disorder is characterised by circulating antibodies which bind a protein in the blood known as Beta 2-Glycoprotein I. The exact role of Beta 2-GPI in the body has not been determined, although there are numerous studies looking at this protein. This protein has been thought to be important in ....Antiphospholipid antibodies are associated with an autoimmune condition characterised by the presence of clots and recurrent miscarriages. Although the name implies that the antibodies bind phospholipid the disorder is characterised by circulating antibodies which bind a protein in the blood known as Beta 2-Glycoprotein I. The exact role of Beta 2-GPI in the body has not been determined, although there are numerous studies looking at this protein. This protein has been thought to be important in controlling the clotting system in humans and other mammals. The evidence for this has been contradictory, however, we have recently made a major new finding on the function of this protein on the clotting system. We will be using sophisticated molecular biology techniques to further characterise the role that Beta 2-GPI has in controlling clotting factors in the body. We have been able to eliminate the gene for Beta 2-GPI in mice thus deriving mice that do not produce any Beta 2-GPI protein. These mice are called Beta 2-GPI knockout mice and will be an ideal animal model to examine the function of Beta 2-GPI and its new role in controlling the clotting cascade by targetting a specific part of this pathway. In addition, these findings may be able to provide new information on how Beta 2-GPI controls clotting factors and the effect of antiphospholipid antibodies on this system, which may lead to new treatments for antiphospholipid antibodies and more generally clotting disorders.Read moreRead less
Development Of Endogenous Granulocyte Colony Stimulating Factor (G-CSF) Antagonism As A New Therapeutic Approach To Inflammatory Disease
Funder
National Health and Medical Research Council
Funding Amount
$401,561.00
Summary
Neutrophils play a pivotal role in inflammatory diseases including rheumatoid arthritis (RA). G-CSF is a growth factor that is important to neutrophil survival and function. We have shown that in the absence of G-CSF the incidence and severity of experimental autoimmune arthritis are reduced. We will investigate the mechanisms by which this occurs as well as studying the effects of G-CSF blockade on function and survival of human neutrophils from healthy donors and RA patients.
The Role Of NF-?B Transcription Factor RelA In Regulatory T Cell Homeostasis And Function
Funder
National Health and Medical Research Council
Funding Amount
$637,114.00
Summary
Treg cells constitute an immune regulatory cell population that is essential for the prevention of fatal autoimmunity; however, they also limit immunity against cancer. We have discovered that the factor RelA is of critical importance for Treg development and function. We now aim to illuminate the functions of RelA in detail. Understanding the molecules that impact on Treg cell biology is critical to harness their potential for clinical intervention such as treatment of autoimmunity and cancer.
Intra- And Intercellular Spreading In Shigella Pathogenesis
Funder
National Health and Medical Research Council
Funding Amount
$216,318.00
Summary
Each year Shigella flexneri bacteria cause over 167 million episodes of dysentery and over 1 million deaths worldwide, under conditions of poor sanitation, in both developed and developing countries. No vaccines are available, and resistance to antibiotics is common. This project will study the a key part of the machinery that allows bacteria use to cause disease, and also to identify drugs that block the machinery which can in future be used to treat infection by these bacteria.